Tuesday Health Partners with Humana to Expand Palliative Care Access
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 14 2026
0mins
Should l Buy HUM?
Source: Newsfilter
- Partnership Announcement: Tuesday Health has announced a partnership with Humana Inc. to launch a new program on June 1, 2026, aimed at providing value-based palliative care for Texans with serious illnesses, marking a significant step in the company's national expansion.
- Service Offerings: The program will provide eligible Humana members and their caregivers with coordinated clinical guidance, proactive symptom management, and ongoing support designed to enhance quality of life and ensure care aligns with individual goals.
- Team Collaboration: Through this partnership, eligible Humana members will gain access to Tuesday Health's interdisciplinary care teams, which include nurses, social workers, nurse practitioners, and physicians, who will work alongside existing clinicians to manage symptoms and guide complex medical decisions.
- Market Demand: According to the Center to Advance Palliative Care, over 12 million Americans currently live with serious illnesses, a number expected to grow significantly as the population ages, making value-based palliative care models essential for improving care experiences and supporting caregivers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 210.340
Low
231.00
Averages
290.39
High
344.00
Current: 210.340
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CVS Health Rises 1.7%, Elevance Increases 2.2%, Cigna Gains 1%, Humana Climbs 3.5%, Molina Healthcare Advances 2.3%
CVS Health Performance: CVS Health reported a 1.7% increase in its performance metrics.
Elevance Health Growth: Elevance Health experienced a growth of 2.2% in its financial results.
Cigna's Financial Status: Cigna saw a 1% rise in its performance indicators.
Humana and Molina Health Care: Humana reported a 3.5% increase, while Molina Health Care experienced a 2.3% growth.
See More
CVS Health Rises 3.3%, Elevance Increases 3.2%, Cigna Gains 1.3%, Humana Climbs 2.9%, Molina Healthcare Up 3% in Premarket Trading
CVS Health Growth: CVS Health reported a growth of 3.3% in its recent performance metrics.
Elevance Health Performance: Elevance Health experienced a 3.2% increase in its financial results.
Cigna's Increase: Cigna saw a 1.3% rise in its performance indicators.
Humana and Molina Health Care: Humana's growth was recorded at 2.9%, while Molina Health Care reported a 3% increase.
See More
U.S. Health Insurer Stocks Climb in Premarket Trading Following UnitedHealth's Q1 Profit Beat
Health Insurers' Stock Performance: U.S. health insurers' shares have seen a rise in the premarket following reports from UnitedHealth indicating a profit in Q1 that exceeds estimates.
Market Reaction: The positive earnings report from UnitedHealth has contributed to an overall increase in investor confidence in the health insurance sector.
See More
Humana Declares Quarterly Dividend of $0.885 per Share
- Quarterly Dividend Announcement: Humana has declared a quarterly dividend of $0.885 per share, consistent with previous distributions, demonstrating the company's ongoing ability to maintain stable cash flows, which is likely to attract income-seeking investors.
- Payment Dates: The dividend will be payable on July 31, with a record date of June 26 and an ex-dividend date also on June 26, ensuring shareholders receive their returns promptly and bolstering confidence in the company.
- Fourteen Consecutive Quarters: Humana has announced the same dividend for fourteen consecutive quarters, indicating stability in financial management and profitability, which may enhance market recognition of its long-term investment value.
- Forward Yield: The current dividend yield stands at 1.78%, providing relative attractiveness in the current market environment, potentially drawing in more income-focused investors and further strengthening the company's market position.
See More
Humana Declares Cash Dividend of $0.885 Per Share
- Dividend Declaration: Humana's Board of Directors has declared a cash dividend of $0.885 per share, scheduled for payment on July 31, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for June 26, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term investment among shareholders.
- Company Overview: Humana is a leading U.S. healthcare company focused on helping millions achieve their best health through insurance services and CenterWell healthcare services, enhancing accessibility and quality of care.
- Broad Service Reach: Humana serves a diverse clientele including Medicare and Medicaid beneficiaries, families, individuals, and military personnel, aiming to improve overall community quality of life and demonstrating the company's commitment to social responsibility in healthcare.
See More
Remote Learning Enhances Respiratory Care Effectiveness
- Significant Educational Impact: A study by Humana Healthcare Research and University of Chicago Medicine in 2020 revealed that nearly 40% of the almost 2000 participants misused their inhalers at the program's start, but after the first phone education session, misuse dropped to below 7%, demonstrating the effectiveness of remote education.
- Importance of Ongoing Education: The research highlighted that continuous multi-session education is crucial for helping patients maintain correct inhaler use over time, with positive outcomes observed across all inhaler types and patient subgroups, underscoring the need for personalized guidance.
- Pharmacists' Key Role: Emily Thomas, a pharmacist at Humana, noted that the phone-based education program offers personalized guidance and support, helping patients improve their inhaler technique and better manage chronic obstructive pulmonary disease (COPD), which is essential for enhancing patients' quality of life.
- Future Research Directions: The study emphasizes the importance of continued research to develop tailored educational approaches for different patients to address the pervasive issue of inhaler misuse, ensuring that patients can effectively use respiratory inhalers to reduce COPD symptoms.
See More
CVS Health Rises 1.7%, Elevance Increases 2.2%, Cigna Gains 1%, Humana Climbs 3.5%, Molina Healthcare Advances 2.3%
CVS Health Performance: CVS Health reported a 1.7% increase in its performance metrics.
Elevance Health Growth: Elevance Health experienced a growth of 2.2% in its financial results.
Cigna's Financial Status: Cigna saw a 1% rise in its performance indicators.
Humana and Molina Health Care: Humana reported a 3.5% increase, while Molina Health Care experienced a 2.3% growth.
See More
CVS Health Rises 3.3%, Elevance Increases 3.2%, Cigna Gains 1.3%, Humana Climbs 2.9%, Molina Healthcare Up 3% in Premarket Trading
CVS Health Growth: CVS Health reported a growth of 3.3% in its recent performance metrics.
Elevance Health Performance: Elevance Health experienced a 3.2% increase in its financial results.
Cigna's Increase: Cigna saw a 1.3% rise in its performance indicators.
Humana and Molina Health Care: Humana's growth was recorded at 2.9%, while Molina Health Care reported a 3% increase.
See More
U.S. Health Insurer Stocks Climb in Premarket Trading Following UnitedHealth's Q1 Profit Beat
Health Insurers' Stock Performance: U.S. health insurers' shares have seen a rise in the premarket following reports from UnitedHealth indicating a profit in Q1 that exceeds estimates.
Market Reaction: The positive earnings report from UnitedHealth has contributed to an overall increase in investor confidence in the health insurance sector.
See More
Humana Declares Quarterly Dividend of $0.885 per Share
- Quarterly Dividend Announcement: Humana has declared a quarterly dividend of $0.885 per share, consistent with previous distributions, demonstrating the company's ongoing ability to maintain stable cash flows, which is likely to attract income-seeking investors.
- Payment Dates: The dividend will be payable on July 31, with a record date of June 26 and an ex-dividend date also on June 26, ensuring shareholders receive their returns promptly and bolstering confidence in the company.
- Fourteen Consecutive Quarters: Humana has announced the same dividend for fourteen consecutive quarters, indicating stability in financial management and profitability, which may enhance market recognition of its long-term investment value.
- Forward Yield: The current dividend yield stands at 1.78%, providing relative attractiveness in the current market environment, potentially drawing in more income-focused investors and further strengthening the company's market position.
See More
Humana Declares Cash Dividend of $0.885 Per Share
- Dividend Declaration: Humana's Board of Directors has declared a cash dividend of $0.885 per share, scheduled for payment on July 31, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for June 26, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term investment among shareholders.
- Company Overview: Humana is a leading U.S. healthcare company focused on helping millions achieve their best health through insurance services and CenterWell healthcare services, enhancing accessibility and quality of care.
- Broad Service Reach: Humana serves a diverse clientele including Medicare and Medicaid beneficiaries, families, individuals, and military personnel, aiming to improve overall community quality of life and demonstrating the company's commitment to social responsibility in healthcare.
See More
Remote Learning Enhances Respiratory Care Effectiveness
- Significant Educational Impact: A study by Humana Healthcare Research and University of Chicago Medicine in 2020 revealed that nearly 40% of the almost 2000 participants misused their inhalers at the program's start, but after the first phone education session, misuse dropped to below 7%, demonstrating the effectiveness of remote education.
- Importance of Ongoing Education: The research highlighted that continuous multi-session education is crucial for helping patients maintain correct inhaler use over time, with positive outcomes observed across all inhaler types and patient subgroups, underscoring the need for personalized guidance.
- Pharmacists' Key Role: Emily Thomas, a pharmacist at Humana, noted that the phone-based education program offers personalized guidance and support, helping patients improve their inhaler technique and better manage chronic obstructive pulmonary disease (COPD), which is essential for enhancing patients' quality of life.
- Future Research Directions: The study emphasizes the importance of continued research to develop tailored educational approaches for different patients to address the pervasive issue of inhaler misuse, ensuring that patients can effectively use respiratory inhalers to reduce COPD symptoms.
See More
